We pursue innovative therapies that address unmet medical needs, guided by a fundamental understanding of the genetics and underlying biology of the conditions we seek to help treat.
¹Trial evaluating an expanded indication of a product which is approved in the United States, Europe and other markets.
²Phase 2 enrollment targeted to begin in Q4 2024.
Updated September 5, 2024